The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects.
MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight loss and smoking cessation, to its portfolio.
MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical studies are advancing this year.
MIRA Pharmaceuticals gains approval for a Phase 1 trial of Ketamir-2 in Israel, aiming to complete by Q4 2025 before moving to Phase 2a in neuropathic pain.
MIRA Pharmaceuticals completes preclinical safety studies for Ketamir-2, confirming no adverse findings as it targets an Investigational New Drug submission by late 2024.
MIRA Pharmaceuticals stock rises as new preclinical data reveal its oral ketamine analog Ketamir-2 is 60% more effective than gabapentin in pain relief.
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) shares are trading higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. Here's what you need to know.
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
MIRA Pharmaceuticals stock surges on promising preclinical results of oral ketamine analog, Ketamir-2, showing 100% pain threshold normalization in rats, positioning it as a potential breakthrough for neuropathic pain treatment.
